ArticleAdvancements in genetic engineering2015
Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy.
Article in Advancements in genetic engineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.Immuno-oncology technology · 2026Article
- TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.Journal for immunotherapy of cancer · 2023Article
- Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.Advanced healthcare materials · 2023Article
- Dendritic cell-mimicking scaffolds for ex vivo T cell expansion.Bioactive materials · 2023Article
- CAR-T: What Is Next?Cancers · 2023Review
- Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.Best practice & research. Clinical haematology · 2021Review
- Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.Blood cancer discovery · 2021Article
- Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4Frontiers in immunology · 2021Article
- Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.Expert review of clinical immunology · 2020Article
- Article
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
- Mechanisms of resistance to CAR T cell therapy.Nature reviews. Clinical oncology · 2019Review
- Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.Frontiers in immunology · 2019Review
- Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.Nature biotechnology · 2018Article
- Surface engineering for lymphocyte programming.Advanced drug delivery reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Adoptive transfer of antigen specific T-cells can lead to eradication of cancer and viral infections. The broad application of this approach has further been hampered by the limited availability of adequate numbers of T-cells for treatment in a timely manner. This has led to efforts for the development of efficient methods to generate large numbers of T-cells with specificity for tumor or viral antigens that can be harnessed for use in cancer therapy. Recent studies have demonstrated that during encounter with tumor antigen, the signals delivered to T-cells by professional antigen-presenting cells can affect T-cell programming and their subsequent therapeutic efficacy. This has stimulated efforts to develop artificial antigen-presenting cells that allow optimal control over the signals provided to T-cells. In this review, we will discuss the cellular artificial antigen-presenting cell systems and their use in T-cell adoptive immunotherapy for cancer and infections.
Indexed as
Identifiers
29644163PMC5891142W2588658675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.